Verrica Pharmaceuticals (1NE0) Stock Price & Analysis
1NE0 Stock Chart & Stats
- Day’s Range
- EUR 2.86 - EUR 2.86
- 52-Week Range
- EUR 2.78 - EUR 7.60
- Previous Close
- EUR 3.05
- Volume
- N/A
- Average Volume (3M)
- 3
- Market Cap
- EUR 51.53M
- Enterprise Value
- EUR 121.00M
- Total Cash (Recent Filing)
- EUR 11.20M
- Total Debt (Recent Filing)
- EUR 1.81M
- Price to Earnings (P/E)
- ―
- Beta
- 1.02
- Next Earnings
- Nov 09, 2026 (Est.)
- EPS Estimate
- -0.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
YCANTH Commercial Traction
YCANTH is showing improving commercial adoption, with dispensed units and net product revenue both increasing sequentially. Continued prescriber uptake and demand from commercially insured patients could support a stronger recurring product-sales base over the next several quarters.
High Product Gross Margins
Gross margins above 90% demonstrate attractive product-level economics and provide meaningful contribution potential as sales scale. Although the margin declined modestly year over year, its sustained level supports future operating leverage if commercial revenue grows faster than corporate expenses.
Partner-backed Pipeline Expansion
External funding and international commercialization arrangements broaden Verrica’s growth opportunities while reducing the company’s direct burden for key development and launch activities. These partnerships preserve global rights outside Japan and Israel and create potential future revenue and milestone sources.
Bears Say
Persistent Unprofitability
Verrica remains materially loss-making despite strong YCANTH product margins, showing that corporate R&D, selling, and administrative costs still exceed the current revenue base. Continued losses reduce internally generated funding capacity and make progress toward sustainable profitability dependent on substantial sales growth or cost control.
Ongoing Cash Consumption
Persistent operating and free-cash-flow deficits mean the business is not yet self-funding its operations or development programs. Even though cash burn improved versus 2024, continued consumption can pressure liquidity and leave future investment capacity dependent on financing, partnerships, or a meaningful improvement in earnings.
Weakening Balance-sheet Cushion
The sharp decline in equity reduces the balance-sheet cushion available to absorb ongoing losses and fund development. Although reported debt is modest, a smaller equity base increases financing risk over the medium term and leaves less flexibility if commercial growth or clinical milestones take longer than expected.
Verrica Pharmaceuticals News
1NE0 FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
What is Verrica Pharmaceuticals’s market cap?
When is Verrica Pharmaceuticals’s upcoming earnings report date?
How were Verrica Pharmaceuticals’s earnings last quarter?
Is Verrica Pharmaceuticals overvalued?
Does Verrica Pharmaceuticals pay dividends?
What is Verrica Pharmaceuticals’s EPS estimate?
How many shares outstanding does Verrica Pharmaceuticals have?
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Verrica Pharmaceuticals Stock Smart Score
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jayson Rieger
- Employees
- 76
- Website
- www.verrica.com
- Address
- 44 West Gay Street Suite 400, West Chester, PA, 19380, US
Verrica Pharmaceuticals (1NE0) Earnings & Revenues
1NE0 Earnings Call
Earnings Call SentimentNeutral
The call presents a mix of clear commercial momentum for YCANTH (robust unit growth, quarter-over-quarter revenue gains, new international distribution, and strong trial progress) and encouraging clinical signals (VP-315 Phase II abscopal effects and active Phase III enrollment for common warts). Offsetting these positives are sizable year-over-year revenue decline driven by last year’s one-time milestone, substantial GAAP and non-GAAP losses, materially higher R&D and SG&A expense, a legal settlement charge, and a relatively modest cash balance that makes the company reliant on a conditional credit facility. Management’s nondilutive financing and Torii’s substantial trial funding materially de-risk near-term liquidity and program funding, but financial outcomes remain contingent on milestone achievement, careful draw decisions, and successful trial readouts.
View all DE:1NE0 earnings summaries1NE0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |
